CARL JUNE, M.D.
Richard W. Vague Professor in Immunotherapy and Director, Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania 
Director, Parker Institute for Cancer Immunotherapy

CARL JUNE is the Richard W. Vague professor in immunotherapy at the Perelman School of Medicine at the University of Pennsylvania, where he is also the director of the Center for Cellular Immunotherapies. In addition, he is the director of the Parker Institute for Cancer Immunotherapy. June graduated from the U.S. Naval Academy and earned his M.D. from the Baylor College of Medicine. He spent his fourth year of medical school at the World Health Organization in Geneva, Switzerland, studying immunology and malaria. June conducted postdoctoral research in transplantation biology at the Fred Hutchinson Cancer Center in Seattle from 1983 to 1986. 

June served as president of the Clinical Immunology Society and is a member of the American Academy of Arts and Sciences, the American Philosophical Society, the National Academy of Sciences, and the National Academy of Medicine. He is a co-founder of Tmunity Therapeutics, Dispatch Biotherapeutics, Capstan Therapeutics, and BlueWhale Bio. CTL019, the CAR T-cell therapy developed in the June laboratory, was the first gene therapy to be approved by the Food and Drug Administration.

Photo courtesy of University of Pennsylvania Perelman School of Medicine